PTJ
NUVB icon

Paul Tudor Jones’s Nuvation Bio NUVB Stock Holding History

Paul Tudor Jones’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-177,260
Closed -$760K – 4055
2026
Q1 		$760K Buy
+177,260
New +$988K ﹤0.01% 2552

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Paul Tudor Jones's NUVB Position: Q2 2026 in Review

Paul Tudor Jones sold out of Nuvation Bio (NUVB) in Q2 2026, closing a stake of 177,260 shares — an estimated $760K sold.

Paul Tudor Jones first reported a position in NUVB in Q1 2026 and held it in 1 quarter. The position peaked at $760K in Q1 2026. 242 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Paul Tudor Jones reported no remaining Nuvation Bio position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 177,260 Nuvation Bio shares in Q2 2026, an estimated $760K.
  • Paul Tudor Jones first reported a position in Nuvation Bio in Q1 2026 and held it in 1 quarter.
  • Paul Tudor Jones's Nuvation Bio position peaked at $760K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.